Sunitinib and Thyroid Atrophy in Kidney Cancer Patients
Author Information
Author(s): Shinohara N, Takahashi M, Kamishima T, Ikushima H, Otsuka N, Ishizu A, Shimizu C, Kanayama H, Nonomura K
Primary Institution: Hokkaido University Graduate School of Medicine
Hypothesis
Does sunitinib treatment lead to thyroid atrophy in patients with metastatic renal cell carcinoma?
Conclusion
Sunitinib treatment frequently causes thyroid atrophy and may lead to irreversible hypothyroidism.
Supporting Evidence
- The median reduction rate in thyroid volume was 30% in all patients.
- Nine patients developed hypothyroidism during treatment.
- Histological evaluation showed atrophy of thyroid follicles.
- Half of the patients in the high reduction rate group exhibited transient TSH suppression.
Takeaway
This study found that a medicine called sunitinib can shrink the thyroid gland in some cancer patients, which can make them feel tired and cold because their body isn't making enough thyroid hormone.
Methodology
Thyroid volume and function were measured at baseline, during treatment, and post-treatment, with histological evaluation in autopsied patients.
Potential Biases
Potential bias due to the observational nature of the study and the lack of a control group.
Limitations
The study had a small sample size and was observational, which may limit the generalizability of the findings.
Participant Demographics
Median age was 62 years, with a mix of previous treatments including IFN-α.
Statistical Information
P-Value
0.083
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website